The urgency behind the initiative is grounded in stark numbers. Texas currently records a cervical cancer incidence rate of 9.5 per 100,000 women, well above the national figure of 7.5 per 100,000. The state ranks eighth in the nation for incidence and sixth for mortality, a combination that signals not only more diagnoses but also worse outcomes for the women who receive them. The disparities run even deeper at the county level, where some Texas communities report incidence rates between 15 and 21 per 100,000 — as much as five times the elimination threshold. The burden falls disproportionately on uninsured women, rural residents, border communities and minority populations, groups that historically face the greatest barriers to vaccination, screening and follow-up care.

Cervical cancer occupies a unique position in oncology: it is one of the few cancers for which near-complete prevention is scientifically achievable. Virtually every case is caused by persistent infection with high-risk types of human papillomavirus (HPV), a common sexually transmitted virus against which highly effective vaccines have existed since 2006. When precancerous lesions are detected through screening and treated promptly, progression to invasive cancer can be interrupted almost entirely. The World Health Organization has embraced this logic globally, setting the same sub-four-per-100,000 threshold as its international elimination benchmark. The Texas plan translates that global framework into a state-specific strategy, acknowledging that the biology of prevention is settled and the remaining challenge is one of delivery, access and follow-through.

The plan was developed by the Cancer Alliance of Texas Cervical Cancer Elimination Priority Area Workgroup, which grounded its recommendations in a survey of stakeholders across the state and a virtual summit that drew more than 250 participants. The resulting document aligns with multiple priorities from the 2024 Texas Cancer Plan, ensuring that the elimination effort is embedded within the state’s broader cancer control architecture rather than operating as a standalone campaign. More than 40 coalition members have already signed a joint declaration outlining their individual commitments, a structure that distributes responsibility across hospitals, clinics, schools, funders and community organizations instead of concentrating it in a single institution.

At the heart of the roadmap are three pillars, each paired with a measurable target for 2032. The first addresses HPV vaccination: the plan calls for raising the percentage of Texas boys and girls who are up to date on HPV vaccination by age 15 from 50.5 percent to 80 percent. That figure matters because vaccination is most protective when administered well before any potential exposure to the virus, and the age-15 benchmark reflects national guidance emphasizing early completion of the vaccine series. Vaccinating both boys and girls is critical, since herd immunity depends on broad coverage across the population and males can carry and transmit the virus even when they face far lower personal risk of HPV-driven cancers themselves.

The second pillar targets screening, with the goal of increasing the share of Texas women who are up to date on cervical cancer screening from 64 percent to 80 percent. The plan explicitly incorporates two technological advances designed to lower the barriers that keep women from being tested. Primary HPV testing, which uses the virus itself as the screening signal rather than relying solely on cytology, offers improved sensitivity and longer intervals between tests. HPV self-collection, meanwhile, allows women to gather their own samples in a clinical setting or potentially outside traditional exam rooms, an option that has shown promise in reaching women who avoid screening because of discomfort, cost, time constraints or distrust of the medical system. Adding these modalities to the state’s screening toolkit is one of the plan’s most consequential technical commitments.

The third pillar confronts a step that is often overlooked in elimination strategies: what happens after an abnormal result. The plan aims to ensure that 80 percent of women receive the diagnostic follow-up and treatment they need when screening detects something suspicious. This stage is where many prevention programs falter, because an abnormal screening result is only the beginning of a cascade that may involve colposcopy, biopsy and treatment of precancerous lesions. Each additional appointment is an opportunity for patients to be lost to the system, particularly among women juggling work, childcare, transportation challenges or lack of insurance. The plan addresses this vulnerability through community outreach, patient navigation, provider training and survivorship support, pairing clinical capacity with human infrastructure that guides patients through every step.

Patient navigation and access expansion are not confined to a single pillar; they are woven across all three, with particular emphasis on rural and border communities and on including people without health insurance. This design choice reflects the epidemiology of the disease in Texas, where geographic and economic isolation translate directly into higher incidence and mortality. Community health workers, known in many Texas communities as promotores, are positioned as central actors in the strategy, bridging the gap between formal health systems and neighborhoods where medical mistrust, language barriers and logistical hurdles suppress participation in vaccination and screening programs.

Coalition leaders framed the effort in explicitly human terms. Ernest Hawk, M.D., vice president and division head of Cancer Prevention and Population Sciences at UT MD Anderson, said that Texas has the tools to prevent nearly every case of cervical cancer but that tools save lives only when people can utilize them. He described the plan as a shared roadmap to vaccinate more children, screen more women and ensure that every abnormal result leads to care, adding that with innovations like HPV self-collection and the commitment of partners across the state, elimination is within reach. Sharyn Malatok, chair of the Cancer Alliance of Texas, emphasized that elimination will happen in clinics, schools, churches and neighborhoods, through community health workers, promotores and navigators who meet people where they are, and that the plan puts those communities at the center of the effort.

The six-year timeline gives the coalition a concrete horizon: if the 2032 targets are met, Texas would join the small group of jurisdictions that have pushed cervical cancer below the elimination threshold, transforming a disease that once killed thousands of American women annually into a rarity detectable only through surveillance. The full plan is publicly available at TexasCancerPlan.org/CCEP, and its architects are calling on policymakers, health systems, schools, funders and community leaders across the state to join the effort. Whether Texas reaches the finish line will depend on sustained funding, vaccination uptake among the state’s large and diverse pediatric population, and the unglamorous work of making sure no abnormal result slips through the cracks — but for the first time, the state has a single, quantified roadmap for getting there.

Subject of Research: A statewide public health plan to eliminate cervical cancer in Texas through HPV vaccination, screening and timely follow-up care

Article Title: New statewide plan aims to eliminate cervical cancer in Texas by 2032

Article References: New statewide plan aims to eliminate cervical cancer in Texas by 2032. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: cervical cancer, HPV vaccination, cancer screening, Texas, MD Anderson, CPRIT, public health, health disparities, HPV self-collection, patient navigation, cancer elimination, preventive oncology

Taylor directs the Pediatric Brain Tumor Research Program at Texas Children’s Cancer and Hematology Center and serves as a professor of pediatrics and neurosurgery at Baylor College of Medicine. He is also a CPRIT Scholar in Cancer Research and holds the Cyvia and Melvyn Wolff Chair of Pediatric Neuro-Oncology at Texas Children’s. His dual identity as an operating surgeon and a laboratory scientist is central to the recognition. Few researchers in pediatric oncology occupy both worlds at once, and Taylor’s career has been built on the conviction that the operating theater and the laboratory must inform each other if children with malignant brain tumors are to receive treatments that are both more effective and less damaging to their developing brains.

The scientific core of Taylor’s work lies in two of the most challenging diagnoses in pediatric neuro-oncology: medulloblastoma and ependymoma. Medulloblastoma, the most common malignant brain tumor of childhood, arises in the cerebellum and has long been treated with a blunt combination of surgical resection, craniospinal radiation, and chemotherapy. Ependymoma, which arises from the ependymal cells lining the ventricles of the brain and the central canal of the spinal cord, presents its own stubborn clinical problems, particularly in young children in whom radiation must be used sparingly. Taylor and his collaborators have helped establish that medulloblastoma is not a single disease but a collection of biologically distinct entities, a reframing that has reshaped how these tumors are studied, classified, and treated around the world.

That conceptual shift matters enormously in practice. When a tumor once treated uniformly is understood to comprise several molecularly defined subgroups, each with distinct cells of origin, signaling pathways, and clinical behavior, the door opens to therapies aimed at the specific biology driving an individual child’s cancer rather than at the tumor’s location alone. Taylor’s laboratory has pursued this logic by investigating how disruptions in early brain development can set the stage for malignancy, and by exploring potential ways to intervene in the processes that drive tumor growth. The developing brain is a landscape of rapidly dividing progenitor cells and precisely choreographed differentiation programs, and cancers of childhood are increasingly understood as diseases in which these developmental programs are hijacked rather than simply damaged.

Methodologically, Taylor’s team combines genetic analysis, computational tools, and laboratory studies to uncover how childhood brain tumors begin and progress. This triad reflects the modern architecture of cancer research: genomic sequencing and related assays generate dense molecular portraits of tumors, computational biology extracts patterns and candidate vulnerabilities from those portraits, and experimental systems in the laboratory test whether the inferred mechanisms can be perturbed to therapeutic effect. The ultimate aim is to identify treatment approaches that improve survival while reducing the long-term effects that children can experience from existing therapies, an especially urgent concern in a population whose brains are still under construction at the time of treatment.

The stakes of that last goal are difficult to overstate. Children who survive malignant brain tumors frequently carry lifelong consequences of the very treatments that saved them, including cognitive impairment, endocrine dysfunction, and the cumulative toll of radiation to the developing nervous system. A therapeutic landscape built on molecular targeting rather than maximal cytotoxicity promises not only better cure rates but better lives after cure. Taylor’s stated goal of translating discoveries about tumor biology into more effective, targeted treatments speaks directly to this dual mandate, and it is a framing that colleagues at Texas Children’s and Baylor have repeatedly emphasized in describing his contribution to the field.

The institutional context of the award is itself part of the story. “The best place in the entire world right now to do high-quality cancer research is the Texas Medical Center,” Taylor said in remarks accompanying the announcement. “A critical mass of clinicians and scientists, with the world’s best technology and positive Texan attitudes. I look forward to seeing what we do in the near future.” The Texas Medical Center in Houston is the largest medical complex in the world, and the co-location of basic research institutes, clinical trial infrastructure, and one of the highest-volume pediatric neurosurgery services anywhere creates conditions in which laboratory discoveries can move toward patients with unusual speed.

Colleagues framed the award in similarly collaborative terms. “Every child with a brain tumor deserves treatments that are more effective and less toxic,” said Dr. Huda Zoghbi, founding director of the Duncan Neurological Research Institute at Texas Children’s and a Distinguished Service Professor and Howard Hughes Medical Institute Investigator at Baylor College of Medicine. “Dr. Taylor has dedicated his career to that goal, and with CPRIT’s generous support and the collaborative environment at Baylor College of Medicine and Texas Children’s Hospital, his work is reaching patients faster.” Zoghbi’s own standing in neuroscience research lends weight to the assessment, and her emphasis on the pipeline from discovery to patients captures what CPRIT funding has been designed to accelerate across the state.

Dr. Tammy Kang, Interim Director of the Texas Children’s Cancer and Hematology Center and Interim Chief of the Division of Hematology-Oncology in the Department of Pediatrics at Baylor College of Medicine, described the honor as a recognition of leadership as much as science. “This award recognizes Dr. Michael Taylor’s vision, scientific leadership, and commitment to improving outcomes for children with brain tumors,” Kang said. “Dr. Taylor has dedicated his career to advancing our understanding of these devastating diseases and translating discoveries into more effective, personalized therapies for patients. We are proud to see his innovative work supported by CPRIT, and we look forward to the impact this research will have for children and families facing brain cancer in Texas and beyond.”

CPRIT, created by a statewide ballot initiative and sustained by legislative reauthorization, has become one of the largest public cancer research funding mechanisms in the United States, and the Texans Conquer Cancer Award now extends its mission from funding to recognition. For the pediatric brain tumor community, the selection of Taylor as one of the first four honorees signals that childhood brain cancers, long underrepresented relative to adult malignancies in research investment, are being treated as a scientific priority in Texas. For the children and families whose tumors his program studies, the award is a marker of momentum: a surgeon-scientist who has spent his career mapping the biology of medulloblastoma and ependymoma now carries an institutional endorsement that his laboratory’s findings are positioned to reach the bedside, where the need for gentler, smarter cures remains one of the most pressing unsolved problems in all of oncology.

Subject of Research: Recognition of pediatric brain tumor research on medulloblastoma and ependymoma through the Texans Conquer Cancer Award

Article Title: Texas Children’s Dr. Michael Taylor honored by CPRIT for advancing childhood brain tumor research

Article References: Texas Children’s Dr. Michael Taylor honored by CPRIT for advancing childhood brain tumor research. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Michael Taylor, CPRIT, Texas Children's Hospital, pediatric brain tumors, medulloblastoma, ependymoma, Baylor College of Medicine, pediatric neurosurgery, cancer research funding, Texans Conquer Cancer Award, pediatric oncology, Texas Medical Center